

# Anchalee Avihingsanon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8723648/anchalee-avihingsanon-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

2,482  
citations

15  
h-index

49  
g-index

72  
ext. papers

2,982  
ext. citations

5.7  
avg, IF

4.13  
L-index

#	Paper	IF	Citations
64	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 795-807	59.2	1791
63	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. <i>Hepatology</i> , <b>2008</b> , 48, 1062-9	11.2	104
62	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. <i>AIDS Research and Therapy</i> , <b>2015</b> , 12, 12	3	67
61	Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. <i>Lancet HIV,the</i> , <b>2016</b> , 3, e410-e420	7.8	61
60	Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3240-5	5.9	32
59	Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 147-55	11.6	32
58	Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , <b>2017</b> , 32, 1945-1955	6.3	29
57	Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1706-14	4	27
56	CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV. <i>AIDS Research and Therapy</i> , <b>2018</b> , 15, 13	3	23
55	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e486-e494	7.8	21
54	Utility of urine lipoarabinomannan (LAM) in diagnosing tuberculosis and predicting mortality with and without HIV: prospective TB cohort from the Thailand Big City TB Research Network. <i>International Journal of Infectious Diseases</i> , <b>2017</b> , 59, 96-102	10.5	20
53	Compulsory drug detention exposure is associated with not receiving antiretroviral treatment among people who inject drugs in Bangkok, Thailand: a cross-sectional study. <i>Substance Abuse Treatment, Prevention, and Policy</i> , <b>2015</b> , 10, 16	3.4	20
52	New-onset diabetes in HIV-treated adults: predictors, long-term renal and cardiovascular outcomes. <i>Aids</i> , <b>2017</b> , 31, 1535-1543	3.5	18
51	Depression and anxiety were low amongst virally suppressed, long-term treated HIV-infected individuals enrolled in a public sector antiretroviral program in Thailand. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2017</b> , 29, 299-305	2.2	17
50	Diabetes mellitus burden among people living with HIV from the Asia-Pacific region. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25236	5.4	15
49	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 453-460	14.3	15
48	Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1993)</i> , <b>2019</b> , 82, 321-328	3.1	15

47	Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161562	3.7	14
46	Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross-Sectional Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0154221	3.7	13
45	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , <b>2018</b> , 32, 985-997	3.5	11
44	Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 64, S171-S178	11.6	10
43	Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008744	7.6	10
42	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. <i>Lancet HIV</i> , <b>2016</b> , 3, e13-22	7.8	8
41	Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. <i>International Journal of Infectious Diseases</i> , <b>2017</b> , 61, 89-96	10.5	8
40	Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 633-9	11.6	8
39	Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230368	3.7	7
38	Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 79, e85-e92	3.1	7
37	Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	6
36	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 118-128	18.8	6
35	Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand. <i>Liver International</i> , <b>2020</b> , 40, 2104-2109	7.9	5
34	Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 69, e36-7	3.1	5
33	Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 41-9	1.6	5
32	Effect of Oral Oseltamivir on Virological Outcomes in Low-risk Adults With Influenza: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2317-2324	11.6	5
31	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23 Suppl 1, e25494	5.4	4
30	Long-Term TDF-Inclusive ART and Progressive Rates of HBSAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 84, 527-533	3.1	4

29	Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database (TAHOD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Asia-Pacific. <i>HIV Medicine</i> , <b>2020</b> , 21, 397-402	2.7	4
28	Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 49, 327-332	14.3	3
27	Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD). <i>HIV Medicine</i> , <b>2019</b> , 20, 439-449	2.7	3
26	Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25264	5.4	3
25	A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 22-7	2.8	3
24	Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV. <i>Southern African Journal of HIV Medicine</i> , <b>2019</b> , 20, 949	1.4	3
23	The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy. <i>HIV Medicine</i> , <b>2020</b> , 21, 64-70	2.7	3
22	Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count. <i>Journal of Virus Eradication</i> , <b>2020</b> , 6, 100005 <sup>2,8</sup>		3
21	Antiretroviral-naïve HIV-infected patients had lower bone formation markers than HIV-uninfected adults. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2020</b> , 32, 984-993	2.2	3
20	Risk factors of chronic hepatitis in antiretroviral-treated HIV infection, without hepatitis B or C viral infection. <i>AIDS Research and Therapy</i> , <b>2013</b> , 10, 21	3	2
19	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD). <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, e25016	5.4	2
18	Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. <i>Hepatology Research</i> , <b>2021</b> , 51, 528-537	5.1	2
17	Performance of a simple flow cytometric assay in diagnosing active tuberculosis. <i>Tuberculosis</i> , <b>2021</b> , 126, 102017	2.6	2
16	Monocyte-to-lymphocyte ratio as a predictor of TB among people living with HIV. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2021</b> , 25, 933-938	2.1	1
15	Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 1234-1245	3.5	1
14	HIV Coinfection Is Associated with Low-Fitness Variants in Rifampicin-Resistant Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	1
13	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , <b>2020</b> , 21, 11-23	1.7	0
12	Response to Screening of diabetes mellitus among people living with HIV - a comment on "Diabetes mellitus burden among people living with HIV from the Asia-Pacific region" (Han et al. 2019). <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25334	5.4	0

11	Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand.. <i>BMC Public Health</i> , <b>2022</b> , 22, 144	4.1	○
10	HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25736	5.4	○
9	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 2009-2022	11.6	○
8	Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy.. <i>Journal of the International AIDS Society</i> , <b>2022</b> , 25, e25900	5.4	○
7	Conference proceedings from the 22nd Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , <b>2020</b> , 15, 211-214	2.4	
6	Mortality following diagnosis of tuberculosis in HIV-infected patients in Asia. <i>HIV Medicine</i> , <b>2018</b> , 19, e70	2.7	
5	The 16th Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , <b>2013</b> , 8, 331-333	2.4	
4	Impact of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/ritonavir trough concentrations in Thai HIV-infected patients. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO3-14-6	○	
3	Conference proceedings from the 23rd Bangkok International Symposium on HIV Medicine. <i>Future Virology</i> , <b>2021</b> , 16, 255-276	2.4	
2	Elimination of hepatitis C among HIV-positive population in Asia: old and new challenges. <i>Future Virology</i> , <b>2021</b> , 16, 407-417	2.4	
1	Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 80, 436-443	3.1	